文献速递泌尿生殖与妇科肿瘤放疗

高危前列腺癌放疗最佳时机:遗漏治疗日是否重要?

Optimal timing of radiotherapy in high risk prostate cancer: Do missed days matter?
PubMed 文献 · Clin Transl Radiat Oncol · 2020-11-25

基于美国国家癌症数据库2004–2015年9610例接受ADT和根治性EBRT的高危前列腺癌患者,中位随访40.6个月。ADT至EBRT间隔>74天及EBRT延长>3天与死亡风险增加相关,EBRT遗漏≥3天者5年OS为79.6% vs 82.9%。

要点

  • ADT至EBRT间隔>74天与死亡风险增加相关(HR 1.20)。
  • EBRT延长>3天与死亡风险增加相关(HR 1.26)。
  • 遗漏≥3天EBRT者5年OS较低(79.6% vs 82.9%)。

核心结论

  • 在高危前列腺癌患者中,ADT至EBRT间隔>74天及EBRT延长>3天与较差OS相关。

研究设计与样本

  • 回顾性队列研究,查询美国国家癌症数据库2004–2015年数据,纳入9610例接受ADT和根治性EBRT的高危前列腺癌患者。

主要发现

  • 中位随访40.6个月,中位年龄72岁,中位PSA 8.7,中位EBRT剂量78 Gy。
  • ADT启动中位时间为诊断后36天,EBRT启动中位时间为诊断后63天,中位延长治疗天数为2.2天。
  • ADT至EBRT间隔>74天与死亡风险增加相关(HR 1.20;p=0.01)。
  • EBRT延长>3天与死亡风险增加相关(HR 1.26;p=0.005)。
  • EBRT延长≥3天者5年OS为79.6%,遗漏≤3天者为82.9%(p=0.0006)。

关键数值与推荐

  • ADT至EBRT间隔>74天与死亡风险增加相关(HR 1.20;p=0.01)。
  • EBRT延长>3天与死亡风险增加相关(HR 1.26;p=0.005)。
  • EBRT延长≥3天者5年OS为79.6%,遗漏≤3天者为82.9%(p=0.0006)。

临床怎么用

  • 在高危前列腺癌接受ADT和根治性EBRT时,应关注ADT至EBRT的间隔时间及治疗中断天数。

局限性

  • 本研究为假设生成性研究,基于国家癌症数据库的回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: High-risk prostate cancer is associated with poorer overall survival (OS) and biochemical control compared to more favorable risk groups. External beam radiation therapy (EBRT) is widely used; however, outcomes data are limited with respect to time elapsed between diagnosis and initiation of EBRT. METHODS: The National Cancer Database was queried from 2004 to 2015 for patients diagnosed with high-risk adenocarcinoma of the prostate who received androgen deprivation therapy (ADT) and definitive EBRT. Logistic regression was utilized to determine covariates associated with missing EBRT treatments. OS was analyzed using multivariate cox proportional hazards models and propensity score matching. RESULTS: 9,610 patients met inclusion criteria with median follow-up of 40.6 months and median age of 72 years. Median PSA was 8.7 and median EBRT dose was 78 Gy. ADT was initiated at a median of 36 days and EBRT at a median of 63 days post-diagnosis. Median number of prolonged treatment days was 2.2. Black race (OR: 1.40; p < 0.01), treatment at a community clinic (OR: 1.32; p < 0.01), and living in an urban/densely populated area were associated with prolonged treatment. Time elapsed between ADT and EBRT > 74 days (HR: 1.20; p = 0.01) and prolonged treatment>3 days of EBRT (HR: 1.26; p = 0.005) were associated with an increased hazard of death. The 5-year OS was 79.6% and 82.9% for patients with prolonged treatment of 3 days or more of EBRT and those missing 3 days or less, respectively (p = 0.0006). CONCLUSION: In this hypothesis-generating study, prolonged treatment delays and missing three or more EBRT treatments was associated with poorer OS in patients with high-risk adenocarcinoma of the prostate.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hasan S, Gorovets D, Lehrer E, et al. Optimal timing of radiotherapy in high risk prostate cancer: Do missed days matter? Clin Transl Radiat Oncol. 2020. PMID: 33305024. doi:10.1016/j.ctro.2020.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。